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(57) ABSTRACT 
A method of treating an anthrax infection wherein a com-
pound of formula I 
(I) 
wherein 
R 1 and R 2 represent, independently of one another unsub-
stituted or specifically substituted C 1 _4 alkoxy; and 
R3 represents hydrogen; cyano; unsubstituted or specifi-
cally substituted C 1_6alkyl; C3 _6cycloalkyl; C2 _6alkenyl; 
C7 _18bicyclyl; aryl, aryl-C1 _4 alkyl, aryl-Q-C1 _4 alkylhet-
eroaryl, heterocyclyl or heterocyclyl-C1_6alkyl, 
wherein aryl denotes a mono- orpoly-nucleous group with 
6 to 14 ring carbon atoms; 
heterocyclyl denotes a 4- to 6-membered non-aromatic 
heterocyclic group comprising 1 to 3, nitrogen, oxygen 
and/or sulfur atoms; heteroaryl denotes a mono- orpoly-
nuclear heteroaromatic group consisting 5- and/or 
6-membered rings and comprising 5 to 13 carbon atoms 
and 1 to 4, nitrogen, oxygen and/or sulfur atoms; and Q 
means -SO- or -SO2-; 
or a pharmaceutically acceptable salt, solvate or hydrate or 
a prodrug thereof; 
is administered to said subject in a quantity effective to 
inhibit, suppress, or expel an anthrax infection in said 
subject. 
20 Claims, No Drawings 
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METHOD FOR THE TREATMENT OF 
ANTHRAX INFECTIONS 
2 
synthesis than TMP. Dogonay &Aydin, Scand J Infect Dis 23: 
333-335, 1991 indicated that TMP-SMZ exhibits a certain 
activity against anthrax, later reports, however, showed that 
clinical isolates of Bacillus anthracis were resistant to TMP-CROSS REFERENCE TO RELATED 
APPLICATION 
This application claims the benefit of U.S. Provisional 
Application No. 60/720,519, filed with the Patent and Trade-
mark Office on Sep. 26, 2005, which application is hereby 
incorporated by reference. 
5 SMZ in vitro (Bakici et al. Scand J Infect Dis 34: 564-566, 
2002). Furthermore it was also shown that the Bacillus 
anthracis Sterne strain was resistant to TMP, with minimal 
inhibitory concentration (MIC) values between 2048 and 
4096 µg/ml (Barrow et al. Antimicrob Agents Chemother 48 
STATEMENT REGARDING FEDERALLY 
SPONSORED RESEARCH OR DEVELOPMENT 
10 (12): 4643-4649, 2004) and that TMP-SMZ was inactive as a 
postexposure prophylactic against anthrax in an animal 
model (Aitboum et al. Infect Immun 70 (11): 6231-6241, 
2002). The very low activity ofTMP on DHFR purified from 
Bacillus anthracis ( concentration at which the enzyme is 
The Government of the United States of America has cer- 15 inhibited by 50% (IC50)=77.2 µM) has been reported as the 
tain rights in this invention pursuant to Grant No. 5 R21 
AI055643-02 awarded by the National Institutes of Health 
through the National Institute Allergy and Infectious Dis-
eases. 
molecular reason for the observed resistance of Bacillus 
anthracis against TMP (Barrow et al. Antimicrob Agents 
Chemother 48 (12): 4643-4649, 2004). 
WO 2004/069255 describes the use of certain 2,4-diami-
BACKGROUND OF THE INVENTION 
The present invention relates to the treatment of anthrax 
infections and to the use of certain 2,4-diaminopyrimidine 
compounds for the manufacture of medicaments for said 
treatment. 
20 noquinazoline or 2,4-diamino-5,6, 7,8-tetrahydroquinazoline 
derivatives as inhibitors for bacterial DHFR, and as agents 
against bacterial infections, mentioning also Bacillus anthra-
cis among a long list of bacteria which could in principle be a 
possible target for said compounds. The reference does how-
25 ever not provide any data whatsoever showing activity against 
Bacillus anthracis or an inhibition ofDHFR isolated thereof. 
Anthrax is a highly infectious disease that normally affects 
animals, for example goats, cattle, sheep or horses, but which 
can be transmitted to humans by contact with infected ani-
mals, infected animal products or Bacillus anthracis spores. 30 
The transmitter of anthrax is a bacterium called Bacillus 
anthracis, an encapsulated Gram-positive, nonmotile, aero-
bic, spore-forming bacterium. Its spores resist destruction 
and remain viable in the soil and in animal products for years, 
even for decades. 35 
Humans are usually infected through the skin or from 
eating meat contaminated with anthrax resulting in cutaneous 
or gastrointestinal forms of anthrax infections. Substantial 
danger may also come from the spores of anthrax, which, 
once inhaled, can result in a disease in the lungs referred to as 40 
pulmonary anthrax or also as woolsorter's disease and which 
is usually fatal. 
Nowadays anthrax is rare in humans in the developed 
industrial countries, however, it still occurs largely in less 
developed countries not sufficiently preventing exposure of 45 
humans to infected animals and their products. 
Furthermore, there is great concern about anthrax as an 
agent of biological warfare and bioterrorism. 
Today, antibiotics are given to unvaccinated individuals 
exposed to inhalation anthrax. Penicillin, tetracyclines and 50 
fluoroquinolones are known to be effective if administered 
within about 24 hours. Ciprofloxin is approved by the FDA 
for a postexposure treatment of inhalational anthrax. 
Nevertheless, there is an ongoing great interest in finding 
new antibacterial drugs for said purpose, for example, as an 55 
alternative for fighting strains of Bacillus anthracis which are 
or become resistant against the present antibiotics. 
SUMMARY OF THE INVENTION 
60 
Trimethoprim (TMP), a compound belonging to the struc-
tural class of the 2,4-diaminopyrimidines, is an antibacterial 
drug well-known in the art as a dihydrofolate reductase 
(DHFR) inhibitor. DHFR is a proven antibacterial target, and 
DHFR inhibitors are used to treat various infections. TMP is 65 
frequently used in combination with sulfamethoxazole 
(SMZ), which acts on a different target enzyme in folic acid 
It has now been found that 2,4-Diaminopyrimidine com-
pounds of formula I 
(I) 
wherein R 1 , R 2 , R3 have the meaning described in more detail 
herein below, exhibit pronounced efficacy in inhibiting 
DHFR of Bacillus anthracis strains. This is particularly sur-
prising in view of the fact that TMP, notwithstanding its 
structural relationship to the compounds of formula I has 
been found ineffective against Bacillus anthracis as indicated 
above. 
The present invention therefore relates to a method of 
treating an anthrax infection in a subject in need of such 
treatment wherein a compound of formula I 
(I) 
wherein 
R 1 and R 2 represent, independently of one another: 
C1_4 alkoxy which may be unsubstituted or substituted with 
amino, mono- or di(C1_4 alkyl)amino, morpholino, piperi-
dino, piperazino, hydroxy, halogen, cyano, thiocyanato, 
US 8,268,825 B2 
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sulfonyl, methylsulfanyl, oxo, carboxy, carbamino, car-





C 1 _6alky I or C3 _6cycloalky I, which both may be unsubstituted 
or substituted with amino, mono- or di(C1_4 alkyl)amino, 
morpholino, piperidino, piperazino, hydroxy, halogen, 
cyano, thiocyanato, sulfonyl, methylsulfanyl, oxo, car-
bamino, carbalkoxy, C1 _4 alkoxy, morpholinoalkoxy or 
piperidinoalkoxy; 
C2 _6alkenyl, which may be unsubstituted or substituted with 
cyano, acryloyl or heterocyclyl; 
C7 _18bicyclyl; 
aryl, aryl-C1_4 alkyl, aryl-Q-C1 _4 alkyl, heteroaryl, heterocy-
clyl or heterocyclyl-C1 _6alkyl, each of which may be 
unsubstituted or substituted with phenyl, C1 _4 alkyl, fluoro-
or polyfluoroC1_4 alkyl, C3 _6cycloalkyl, hydroxy, cyano, 
thiocyanato, amino, mono- or di(C1_4 alkyl)amino, 
hydroxy-C1 _4 alkyl, which may be esterified with an amino 
acid or sulfuric acid, halogen, C1_4 alkoxy, C1_4 alkoxycar-
bonyl; carbamoyl, mono- or di(C1_4 alkyl)carbamoyl, 
C1 _4 a]kylsulfanyl, C1 _4 alkylsulfonyl, sulfamoyl, N-mono-
4 
types, e.g. methoxy, ethoxy, n-propoxy, isopropoxy, n-buty-
loxy, 2-methyl-propoxy, isobutyloxy and tert-butoxy, for 
example. 
C1 _6alkyl where used in this application means preferably 
5 C1_4 a]kyl. C1 _6alkyl or C1_4 alkyl groups in formula I may be 
straight or branched chain groups, and include groups like 
methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert.-
butyl, n-pentyl and n-hexyl. 
Examples ofC1_8cycloalkyl are e.g. cyclopropyl, cyclobu-
10 tyl, cyclopentyl, cyclohexyl or cycloheptyl. 
The above groups may be substituted by one, two or more 
substituents, typical substituents being selected from amino, 
mono- or di(C1_4 alkyl)amino, morpholino, piperidino, piper-
azino, hydroxy, halogen, cyano, thiocyanato, sulfonyl, meth-
15 ylsulfanyl, oxo, carbamino, carbalkoxy, C1_4 alkoxy, mor-
pholinoalkoxy or piperidinoalkoxy. Methoxymethyl, 
hydroxymethyl, hydroxybutyl, dihydroxybutyl, 2-oxo-pro-
pyl, 3-oxo-propyl, perfluorohexyl, cyclopentanonyl, cyclo-
hexanonyl and the like are examples of such substituted alkyl 
20 and alkoxy groups. Preferably the C1 _4 alkoxy, C1 _6alkyl or 
C1_8cycloalkyl groups of the compounds of formula I are 
unsubstituted. 
or di(C1_4 alkyl)sulfamoyl, heterocyclyl, or heterocyclyl- 25 
C1 _4 alkyl; aryl-C1_4 alkyl; 
C2 _6alkenyl is meant herein to embrace unsaturated hydro-
carbon residues containing a double bond, in particular resi-
dues such as vinyl, ally!, butenyl and the like. The alkenyl 
chain is optionally substituted by one or more substituents, 
wherein furthermore 
aryl denotes a mono- orpoly-nucleous group with 6 to 14 ring 
carbon atoms 
heterocyclyl denotes a 4- to 6-membered non-aromatic het- 30 
erocyclic group comprising 1 to 3, nitrogen, oxygen and/or 
sulfur atoms; 
heteroaryl denotes a mono- or polynuclear heteroaromatic 
group consisting of 5- and/or 6-membered rings and com-
prising 5 to 13 carbon atoms and 1 to 4 nitrogen, oxygen 35 
and/or sulfur atoms; and 
Q means -SO- or -SO2-; 
a pharmaceutically acceptable salt, solvate or hydrate or a 
prodrug thereof; 
is administered to said subject in a quantity effective to 40 
inhibit, suppress, or expel an anthrax infection in said 
subject. 
In another aspect the present invention relates to the use of 
a compound of formula I as described herein above for the 
manufacture of a medicament for the treatment of an anthrax 45 
infection. 
such as, for example, cyano acryloyl, or heterocyclyl, as 
defined herein. 
Examples for preferred bicyclyl groups are adamantyl or 
bicyclo[2.2.l]hept-2-endo- and/or 2-exo-yl. 
Preferred examples of suitable aryl groups are phenyl, 
naphthyl, anthryl and phenanthryl, which can be substituted 
by one or more substituents. Suitable substituents for either 
mentioned aryl groups are e.g. phenyl; C1 _6alkyl (e.g. 
methyl); substituted C1 _6alkyl as defined above (e.g. trifluo-
romethyl, pentafluoro ethyl); C3 _6cycloalkyl ( e.g. cyclopro-
pyl); hydroxy; cyano; thiocyanato; amino; hydroxyalkyl, 
optionally esterified with amino acids or sulphuric acid ( such 
as, for example, 2-amino-propionic acid ester or 2-amino-5-
guanidino-pentanoic acid ester); halogen (e.g. chlorine); 
C1_4 alkoxy (e.g. methoxy, n-butoxy); substituted C1_4 alkoxy 
as described above; C1 _4 alkoxycarbonyl ( e.g. methoxycarbo-
nyl); di(C1 _4 alkyl)amino (e.g. dimethylamino, diethy-
lamino ); carbamoyl, mono- or di-C1_4 alkylcarbamoyl; C1 _4 
alkylsulphanoyl, ( e.g. methylsulphanyl); C1_4 alkylsulphonyl, 
(e.g. methanesulphonyl); sulphamoyl, N-mono- or di-C1 _4 
alkylsulphamoyl; heterocyclyl, or with heterocyclyl-C1 _6 
alkyl. Additionally, aryl can be substituted by two vicinal 
alkoxy groups which form a fused ring, such as, for example, 
A better understanding of the present invention, its several 
aspects, and its objects and advantages will become apparent 
to those skilled in the art from the following detailed descrip-
tion, taken in conjunction with the attached drawings, 
wherein there is shown and described the preferred embodi-
ment of the invention, simply by way of illustration of the best 
mode contemplated for carrying out the invention. 
50 2,3-dihydro-benzo[l,4]dioxin-6-yl and benzo[l,3]dioxin-5-
yl. Preferably the aryl groups are unsubstituted. 
DETAILED DESCRIPTION OF THE PREFERRED 
EMBODIMENTS 
The compounds of formula I and their general usefulness 
for the treatment of bacterial infections by virtue of their 
DHFR inhibiting efficacy, in particular for the treatment of 
infections caused by resistant pneumococci and opportunistic 
pathogens such as Pneumocystis carinii are known from EP-
A-0 966 464. 
Examples for the meaning of the term "heterocyclyl" 
include groups derived from e.g. lactones, lactames, cyclic 
ketals (such as, for example, 2-dimethyl-1,3-dioxolan-yl), 
55 cyclic acetals (e.g. 1,3, dioxolan-2-yl or 1,3,-dioxan-2-yl). 
More specific examples ofheterocyclyl groups are morpho-
lin-4-yl, 4-methyl-piperazin-1-yl, imidazol-1-yl, thiazolyl 
and [1,2,4]triazol-1-yl, dithianyl, tetrahydropyranyl. Thehet-
erocyclic rings can be substituted with substituents described 
60 above for the aryl and lower alkyl groups. Such substituents 
are especially lower alkyl, lower alkoxy, hydroxy, amino, 
hydroxyalkyl, aminoalkyl or oxo. Pyrrolidinone, methylpyr-
rolidinone and the like are examples of particularly preferred 
For the purposes of this application the term compound of 
formula I includes all epimers, enantiomers and diastere- 65 
omers and mixtures thereof. The term C1 _4 alkoxy as meant 
with regard to formula I includes straight or branched chain 
substituted heterocyclic rings. 
The term "heterocyclyl-C1 _6alkyl" embraces in the scope 
of the present invention heterocyclic rings which are linked 
via an C1 _6alkyl residue. Preferred heterocyclyl-C1 _6alkyl 
US 8,268,825 B2 
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Theheteroaryl groups R3 can be mono-, di- ortri-substituted, 
independently of one another e.g. by C1_4 alkyl such as e.g. 
methyl, ethyl; substituted C1_4alkyl such as e.g. hydroxym-
ethyl, hydroxy-I-methyl-ethyl; halogen, preferably fluoro, 
units are e.g morpholin-4-ylmethyl, 4-methyl-piperazin-1-
ylmethyl, imidazol-1-ylmethyl and [1,2,4]triazol-1-ylm-
ethyl, dioxolan-4-ylethyl, pyrrolidinylmethyl, pyperidinylm-
ethyl and the like. The heterocyclyl and C1_6alkyl groups can 
each be unsubstituted or substituted as provided for above. 
The term "heteroaryl" denotes residues like, for example, 
fury!, pyranyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, triaz-
olyl, tetrazolyl, oxazolyl, oxadiazolyl, isoxazolyl, thiazolyl, 
isothiazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, tri-
azinyl. These groups can also be linked with a fused ring, 
preferably a phenyl ring. Examples of such linked rings are, 
for example, benzopyranyl, benzofuranyl, indolyl and quino-
linyl. The heteroaryl groups can be substituted, for example 
with substituents as described above for the aryl andC1_6alkyl 
groups. Additionally, heteroaryl can be substituted by two 
vicinal alkoxy groups which form a fused ring, such as, for 
example, [1,3]dioxolo[ 4,5-b ]pyridin-6-yl. 
5 chloro, bromo; C1_4 alkoxy such as e.g. methoxy; substituted 
C1_4 alkoxy such as e.g. methoxy-ethoxy, methoxy-ethoxy-
ethoxy, hydroxy-ethoxy, hydroxypropoxy, 2-morpholin-4-
yl-ethoxy, dimethylamino-ethoxy; benzyloxy; dimethy-
lamino; amino-carbonyl; tert. -buty I-amino-carbonyl; 
10 heterocyclyl like morpholin-4-yl. 
Particularly preferred for use in the treatment of anthrax 
infections or for use in the manufacture of medicaments for 
the treatment of such infections corresponding to the pur-
As used herein, halide or halogen refer to chloride or chlo-
rine, fluoride or fluorine, bromide or bromine, and iodide or 
iodine. 
15 poses of the present invention are compounds of the above 
formula I wherein R 1 and R 2 represent, independently of one 
another C1_4 alkoxy or N-morpholino-C1_4alkoxy, in particu-




Even more preferred for use in the treatment of anthrax are 
the compounds of the above formula I, wherein R 1 and R 2 are 
both C1_4 alkoxy and most preferably methoxy. Regarding the 
group R3 such compounds of formula I are especially pre-
In formula I the group R1 is preferably methoxy; R2 is 
preferably hydroxy, C1_4 alkoxy such as e.g. methoxy or 
ethoxy; or C1_4alkoxy substituted by C1_4alkoxy, such as e.g. 
methoxymethoxy; C1_4alkoxy substituted by heterocyclyl 
such as e.g. morpholin-4-yl-ethoxy or C1_4 alkoxy substituted 
by C1_4 alkoxycarbonyl-C1_6alkyl, preferably methoxycarbo-
nylmethyl 
25 ferred wherein R3 stands for C1_6alkyl or C3 _8cycloalkyl, 
which both may be unsubstituted or substituted with halogen; 
or aryl, aryl-C1_4alkyl, heteroaryl, heterocyclyl or heterocy-
clyl-C1_6alkyl, in particular wherein R3 stands for unsubsti-
tuted C1_6alkyl, preferably C3 _4 alkyl; or C3 _6cycloalkyl, pref-Preferred C1_6alkyl groups R
3 include the following 
groups: methyl; ethyl; propyl; n-butyl, 3-methyl-butyl and 
tert.-butyl, in particular butyl and more particular ethyl. Pre-
ferred substituents for the C1_6alkyl residue R
3 include the 
following substituents: hydroxy such as e.g. hydroxypropyl, 
hydroxybutyl, 3,4-dihydroxybutyl; methylsulfanyl such as 
e.g. methylsulfanylmethyl; fluoro such as e.g. tridecafluo- 35 
rhexyl; carbamoyloxy such as e.g. carbamoyloxy-butyl, car-
bamoyloxy-propyl; thiocyanato such as e.g. thiocyanatobu-
tyl; -SO4 H such as e.g. sulfatobutyl; or heterocyclyl such as 
e.g. [1.3]dioxolan-2-yl-ethyl, [1.3]dioxolan-4-yl-ethyl; het-
erocyclylcarbonyloxy such as e.g. morpholinylcarbonyloxy-
butyl. 
30 erably C5 _6cycloalkyl, or most preferable for aryl, in 
particular phenyl. 
Presently most preferred for the treatment of anthrax are 
the compounds of formula I wherein R1 and R2 are both 
methoxy and R3 is either propyl or phenyl. 
Those compounds of formula I in which R3 is different 
from hydrogen can be present in racemic form or as the R- or 
S-enantiomer or any mixture of said enantiomers. 
Specific examples of preferred compounds of formula I 
useful as inhibitors of DHFR of Bacillus anthracis and 
40 accordingly for the treatment of infections caused by strains 
of said Bacillus and for manufacture of medicaments for such 
Preferred substituents for the alkenyl-residue R3 include 
cyano such as e.g. cyanobutenyl; or acryloyl such as e.g. 
acryloylbutenyl. 
Preferred C3 _6cycloalkyl groups R
3 include cyclopropyl, 45 
cyclobutyl, and in particular cyclopentyl and cyclohexyl. 
Said cycloalkyl groups may be substituted e.g. by an oxo 
group but are most preferably unsubstituted. 
Preferred heterocyclyl- or substituted heterocyclyl-resi-
dues R3 include: dithian-2-yl or tetrahydropyran-2-on-1-yl. 
Examples for the group "aryl-Q-C1_6alkyl" include phe-
nylsulfonylmethyl or phenylsulfinylmethyl. 
50 
The preferred aryl group R3 is phenyl. Said phenyl residue 
can be mono, di- or tri-substituted by C1_6alkyl such as e.g. 
methyl, ethyl, butyl, tert-butyl; substituted C1_6alkyl such as 55 
e.g. hydroxymethyl, hydroxy-ethyl, methoxymethyl, trifluo-
rmethyl; halogen, preferably fluoro; methylsulfanyl; dim-
ethylamino; dimethylamino sulfonyl; cyano; hydroxy; 
C1_4 alkoxy such as e.g. methoxy; substitutedC1_4alkoxy such 
as e.g. hydroxyethoxy, trifluoromethoxy, 1-ethoxy-ethoxy, 60 
2-ethoxy-ethoxy; C1_4alkoxy-carbonyl such as e.g. tert.-bu-
toxy carbonyl; heteroaryl such as e.g. pyrrol-1-yl; heterocy-
clyl-C1_6alkyl such as e.g. 4-methyl-piperazin-1-yl-methyl, 
4-morpholin-4-yl-methyl. 
Preferred heteroaryl groups R3 include pyridyl, pyrimidi- 65 
nyl, thiophen-2-yl, 5,6-dihydro-4H-pyran-2-yl, furan-2-yl, 
thiazol-2-yl, [1,3]dioxolo[ 4,5-b ]pyridin-6-yl. 



















as well as the pharmaceutically acceptable salts of these com-
pounds. 
The compounds of formula I can for instance be prepared 
according to the methods described in EP-A-0 966 464, 
which virtually exemplifies most of the compounds of for-
mula I specifically mentioned herein, or in an equivalent or 
analogous way. 
US 8,268,825 B2 
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IC50 Determination (Enzyme Inhibition Assay) 
In more detail, the inhibition of both human and Bacillus 
anthracis DHFR is determined with the following procedure. 
For drug inhibition assays a solution of each drug is pre-
The compounds of formula I can also be used for the 
treatment of anthrax in form of pharmaceutically acceptable 
acid addition salts with organic and inorganic acids. 
Examples of acid addition salts of compounds of formula I are 
salts with mineral acids, for example hydrohalic acids, such 5 pared at a concentration of 1.024 mg/ml in dimethylsulfoxide 
(DMSO). Dilutions of this drug concentration are further 
prepared in DMSO (1:3, 1:10, 1:30, 1:100, 1:300, 1:1,000, 
1 :3,000, 1 :30,000). The nM concentration of drug in these 
dilutions is calculated based on the molecular weight. Ten 
10 microliters of each drug dilution is tested in an inhibition 
as hydrochloric acid, hydrogen bromide and hydrogen iodide, 
sulphuric acid, nitric acid, phosphoric acid and the like, salts 
with organic sulphonic acids, for example with alkyl- and 
aryl-sulphonic acids such as methanesulphonic, p-toluene-
sulphonic, benzene-sulphonic acid and the like, as well as 
salts with organic carboxylic acids, for example with acetic 
acid, tartaric acid, maleic acid, citric acid, benzoic acid, sali-
cylic acid, ascorbic acid and the like. Such salts can be pre-




The reaction mixture (1.0 ml) contains (1) 100 µl of !Ox 
assay buffer (500 mM potassium phosphate buffer, 10 mM 
ethylenediaminetetraacetic acid (EDTA), pH 7.0: concentra-
tion in reaction mixture is 50 mM potassium phosphate 
buffer-I mM EDTA, pH 7.0), (2) 100 µl 2-mercaptoethanol 
(100 mM: concentration in reaction mixture is 10 mM), (3) 
680 µl water, ( 4) 50 µl reduced nicotinamide adenine dinucle-
The formation of solvates of the compounds of formula I 
including hydrates may vary depending on the compound and 
the solvate. In general, solvates are formed by dissolving the 
compound in the appropriate solvent and isolating the solvate 
by cooling or using an antisolvent. The solvate is typically 
dried or azeotrope under ambient conditions. 
The term "prodrug" as meant in this application, refers to 
any compound which is metabolized either by the subject to 
which is administered or by the anthrax bacilli with which the 
subject is infected. The design of prodrugs is described, for 
example, in "Design of Prodrugs", edited by Hans Bund-
gaard, 1985 Elsevier Science Publishers B.V. 
20 otide phosphate (NADPH) (2 mM: concentration in reaction 
mixture is 0.1 mM), (5) 10 µl enzyme (containing 0.66 µgin 
125 mM potassium phosphate buffer, 2.5 mM EDTA, 0.1 % 
bovine serum albumin, pH7), ( 6) 10 µl of drug dilution. 
This mixture is heated for 3 minutes in a 30° C. water bath, 
The term "treating an anthrax infection" is understood as 
obtaining results beneficial for the infected subject, in par-
ticular beneficial clinical results. Such results include, in par-
ticular, that an anthrax infection is either inhibited in said 
subject, suppressed or expelled or at least alleviated. "Inhib-
iting an anthrax infection" means that a subject which cannot 
reasonably avoid to get in contact with Bacillus anthracis, has 
25 followed by the addition of (7) 50 µl dihydrofolate (2 mM: 
concentration in the reaction mixture is 0.1 mM). The solu-
tion is read for 3 minutes at 340 nm in a spectrophotometer, 
and the activity is measured as the decrease in the optical 
density at 340 nm (O.D. 340) over 3 minutes at 30° C. 
30 This is compared with a control reaction in which all con-
ditions and reagents are the same with the exception that 10 µl 
ofDMSO (no drug) is used. 
The percent inhibition in each reaction is calculated using 
35 
the following formula: 
a significantly reduced risk to develop an anthrax infection as 
compared to the risk of a subject under the same conditions 
who has not got a treatment with a compound of formula I. 
"Suppressing an anthrax infection" means, in particular, that 40 
a subject definitely having been in contact with Bacillus 
anthracis or spores thereof, e.g. by inhaling such Bacillus or 
spores, has a significantly reduced risk, when compared with 
an untreated subject under the same conditions, of developing 
dangerous or even life-threatening symptoms of an anthrax 45 
infection, if the treatment with compounds of formula I com-
mences after said contact of the subject with the bacilli or 
spores. "expelling an anthrax infection" means that a subject 
already having one or more symptoms of a manifest anthrax 
infection has a significantly increased chance for overcoming 50 
that infection, preferably without substantial aftermath. 
A subject is preferably a human, but may also be an animal 
susceptible to anthrax infection, in particular a ruminant such 
as a horse, a cow, a sheep or a goat. 
The inhibition of dihydrofolate reductase of Bacillus 55 
anthracis is taken as a measurement of the activity of the 
compounds of formula I against anthrax infections. 
For determining the inhibiting activity of the compounds 
measurements ofIC50 and MIC are performed. 
% inhibition~l00-((L\. O.D. 340 inhibition reaction//\. 
O.D. 340 control reaction)xl00) 
An IC50 value is generated by using KC Junior software 
(Bio-Tek Instruments, Inc.) which plots log10 of the drug 
concentration versus % Inhibition. 
Each reported IC50 is the average of two or more determi-
nations. 
2) MIC Determination: 
MIC values are determined in 96-well microtiter plates pre-
pared according to the NCCLS broth microdilution reference 
method (i.e. alamarB!ue™ microdilution broth assay). 
Details of the method are described in Barrow et al. Antimi-
crob Agents Chemother 48 (12): 4643-4649, 2004. 
In more detail, the minimal inhibitory concentration (MIC) 
of compounds against Bacillus anthracis Sterne is deter-
mined using an alamarB!ue™ microdilution broth assay. 
96-well microtiter panels of test compounds and control anti-
biotics are prepared according to the NCCLS broth microdi-
lution reference method in cation-adjusted Mueller-Hinton 
broth (BD) containing 10% alamarB!ue™ (CAMHB/10% 
aB) dye reagent (Biosource Int. Ca), (NCCLS, January 2003, 
"Methods for dilution antimicrobial susceptibility tests for 
1) IC50 Measurement: 60 bacteria that grow aerobically"; approved standard-6
th edi-
tion, M7-A6, vol. 23, No. 2). DHFR catalyses the conversion of dihydrofolate into tetrahy-
drofolate and concomitantly oxidizes the cofactor NADPH 
into NADP. These conversions cause a decrease of absor-
bance at 340 nm, which can be measured to follow the 
enzyme reaction. A detailed description of the assay is pub- 65 
lished (Barrow et al. Antimicrob Agents Chemother 48 (12): 
4643-4649, 2004). 
MIC Drug Plates Preparation: 
Screening MIC drug plates contain test compounds at four 
concentrations (10-fold dilutions) in CAMHB/10% aB: 
0.128, 1.28, 12.8 and 128 µg/ml. These drug concentrations 
are prepared from -20° C. frozen stocks of each drug solubi-
lized in sterile DMSO. 
US 8,268,825 B2 
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Quality control (QC) antibiotics are prepared from -80° C. 
aqueous stocks at 2-fold dilutions in CAMHB/10% aB. 
Doxycycline is prepared at 0.25, 0.5 and 1.0 µg/ml. 
TMP/SMZ is prepared at 1.25/4.75, 0.5/9.5, 1.0/19, and 
2/38 µg/ml. 
Sterility and growth control wells contain CAMHB/10% 
aB while solvent control wells contain CAMHB/10% aB with 
appropriate concentrations of sterile DMSO. 
5 
Once screening assays are completed, MIC drug plates are 
prepared with test drugs at 2-fold dilutions in CAMHB/10% 10 
aB. Drug concentrations vary from drug to drug based on 
MIC screening results. 
All wells in the microtiter panels contain 100 µI. 
10 
for bacteria that grow aerobically"; approved standard-6th 
edition, M7-A6, vol. 23, No. 2). A 1 :20 dilution of this solu-
tion is prepared in CAMHB/10% aB. 
All wells with the exception of sterility and color control 
wells are inoculated with 10 µl of the inoculum. Microdilu-
tion panels are placed in a gas-diffusable polypropylene bag 
and incubated at 37° C. in ambient air for 16 hours. 
The colony forming units (cfu) in the final inoculum is 
verified by inoculating appropriate dilutions on TSA blood 
agar and determining the number of colonies after overnight 
incubation. The final inoculum is 5xl05 cfu/ml or 5xl04 
cfu/100 µl as recommended by CLSI. 
Test compounds are plated in triplicates, while sterility 
controls, solvent controls and QC drugs are plated in dupli-
cate. 
15 
Following incubation, results were read visually and spec-
trophotometrically in a microplate reader programmed to 
subtract the absorbance at 600 nm from that at 570 nm. The 
MIC is reported as the lowest drug concentration yielding a Escherichia coli, ATCC 25922, is used to validate doxycy-
cline performance. 
TMP/SMZ is used against Enterococcus faecalis ATCC 
20 
29212 to validate the medium for antifolate testing. 
Doxycycline is used as a QC drug against Bacillus anthra-
cis Sterne at 0.25, 0.5, and 1.0 µg/ml. 
These drugs and their concentrations are used based on 
CLSI interpretive standards for Bacillus anthracis, Escheri-
25 
chia coli, andEnterococcusfaecalis. (CLSI, Ml00-15, Vol. 
25 No. 1). 
Inoculum Preparation and Plate Infection: 
Bacillus anthracis Sterne is subcultured twice on Trypti-
case soy agar (TSA) plates containing 5% sheep blood (Hardy 
30 
Diagnostics, Ca). Cultures are incubated at 37° C. overnight. 
Growth is transferred to 5 ml sterile saline and suspended to 
a turbidity of a 0.5 McFarland standard (NCCLS, January 
2003, "Methods for dilution antimicrobial susceptibility tests 
Compound of formula I 
Trimethoprim 
o'--
differential absorbance of zero or less (i.e., color remains 
blue). 
MIC values are compared to acceptable limits for QC 
strains to validate drug performance. All quality control tests 
must fall within acceptable ranges (Escherichia coli, doxy-
cycline 0.5-2.0 µg/mL, Bacillus anthracis, doxycycline~ 1.0 
µg/mL, Enterococcus faecalis TMP/SMZ~0.5/9.5 µg/mL) 
for results to be considered valid. 
The following Table contains the mentioned values deter-
mined for representative members of the class of compounds 
defined by formula I and determined in the above tests. The 
IC50 values (nM) for DHFR of Bacillus anthracis and for 
human DHFR are given, furthermore the MIC values of the 
respective compounds for Bacillus anthracis. The corre-
sponding values for TMP are also given for comparison. 
MIC 
IC50 (nM) IC50 (nM) B. anthracis 
B. anthracis DHFR humanDHFR (ug/ml) 
7.7 X 104 1.6 X 106 >2000 
54 110000 13 
46 >16000 26 
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-continued 























A preferred embodiment of the present invention is a 
method as described above, wherein a compound of formula 
12 
MIC 
IC50 (nM) ICso (nM) B. anthracis 
B. anthracis DHFR humanDHFR (ug/ml) 
170 >20000 :"'13 
260 >19000 :"'13 
200 >21000 :"'26 
170 >16000 :"'32 
method further comprising the selection of a compound of 
formula I as a candidate for in vivo and/or clinical tests based 
on the efficacy in inhibiting DHFR of Bacillus anthracis in 
vitro found for said compound. 
I is administered which exhibits in vitro an IC50 value for 60 
human DHFR which is at least 70 times, more preferably at 
least 100 times, most preferably at least 250 times as high as 
that for DHFR of Bacillus anthracis. 
The compounds of formula I and the salts, solvates, 
hydrates or prodrugs thereof are preferably formulated into 
pharmaceutical compositions for administration to human 
65 subjects in a form suitable for administration in vivo. Making 
the pharmaceutical preparations can be effected in a manner 
which will be familiar to any person skilled in the art by 
A further object of the present invention is a method for 
inhibiting DHFR of Bacillus anthracis in vitro, wherein a 
compound of formula I is applied to an assay for determining 
the inhibition ofDHFR of Bacillus anthracis, and a respective 
US 8,268,825 B2 
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bringing the substances in accordance with the invention, 
optionally in combination with other therapeutically valuable 
substances, into a galenical administration form together with 
suitable, non-toxic, inert therapeutically compatible solid or 
liquid carrier materials and, if desired, the usual pharmaceu- 5 
tical adjuvants. 
Both inorganic and organic carrier materials are suitable as 
such carrier materials. Thus, for example, lactose, corn starch 
or derivatives thereof, talc, stearic acid or its salts can be used 
as carriers for tablets, coated tablets, dragees and hard gelatin 10 
capsules. Suitable carriers for soft gelatin capsules are, for 
example, vegetable oils, waxes, fats and semi-solid and liquid 
polyols ( depending on the nature of the active ingredient no 
carriers are, however, required in the case of soft gelatin 
capsules). Suitable carrier materials for the production of 15 
solutions and syrups are, for example, water, polyols, sucrose, 
invert sugar and glucose. Suitable carrier materials for injec-
tion solutions are, for example, water, alcohols, polyols, glyc-
erol and vegetable oils. Suitable carrier materials for supposi-
tories are, for example, natural or hardened oils, waxes, fats 20 
and semi-liquid or liquid polyols. 
The usual preservatives, solubilizers, stabilizers, wetting 
agents, emulsifiers, sweeteners, colorants, flavorants, salts for 
varying the osmotic pressure, buffers, masking agents and 
antioxidants come into consideration as pharmaceutical adju- 25 
vants. For parenteral administration the compounds of for-
mula I and, respectively, their salts are preferably provided as 
lyophilizates or dry powders for dilution with usual carriers 
such as water or isotonic saline. 
In accordance with the method of the invention, com- 30 
pounds of formula I or salts, solvates, hydrates or prodrugs 
thereof may be administered to a subject in a variety of forms 
depending on the selected route of administration, as will be 
understood by those skilled in the art. The compounds or 
compositions may be administered, for example, by oral, 35 
parenteral, buccal, sublingual, nasal, rectal, patch, pump or 
transdermal administration and the pharmaceutical composi-
tions formulated accordingly. Parenteral administration 
includes intravenous, intraperitoneal, subcutaneous, intra-
muscular, transepithelial, nasal, intrapulmonary, intrathecal, 40 
rectal and topical modes of administration. Parenteral admin-
istration may be by continuous infusion over a selected period 
of time. 
14 
able solutions or dispersions. In all cases the form must be 
sterile and must be fluid to the extent that easy syringability 
exists. 
Compositions may also be formulated as aerosols, drops, 
gels, cremes and powders. Aerosol formulations typically 
comprise a solution or fine suspension of the active substance 
in a physiologically acceptable aqueous or non-aqueous sol-
vent and are usually presented in single or multidose quanti-
ties in sterile form in a sealed container. Such formulations 
may be used with a propellant which can be a compressed gas 
such as compressed air or an organic propellant such as fluo-
rochlorohydrocarbon. The aerosol dosage forms can also take 
the form of a pump-atomizer. 
Compositions suitable for buccal or sublingual administra-
tion include tablets, lozenges, and pastilles, wherein the 
active ingredient is formulated with a carrier such as sugar, 
acacia, tragacanth, or gelatin and glycerine. 
Compositions for rectal administration are conveniently in 
the form of suppositories containing a conventional supposi-
tory base such as cocoa butter. 
The dosage of the compounds of Formula I or salts, sol-
vates, hydrates or prodrugs thereof can vary depending on 
many factors such as the pharmacodynamic properties, of the 
compound, the mode of administration, the age, health and 
weight of the recipient, the nature and extent of the symp-
toms, the frequency of the treatment and the type of concur-
rent treatment, if any, and the clearance rate of the compound. 
One of skill in the art can determine the appropriate dosage 
based on the above factors. The compounds may be admin-
istered initially in a suitable dosage that may be adjusted as 
required, depending on the clinical response. A daily dosage 
of about 0.2 g to about 2 g, preferably 0.5 to 2 g of a compound 
of formula I in accordance with the invention comes into 
consideration for adults. 
Compounds of Formula I or salts, solvates, hydrates or 
prodrugs thereof, may be used alone or in combination with 
other types ofDHFR inhibitors or with other agents that treat 
anthrax infections like for example quinolones, rifampin, tet-
racycline, vancomycin, imipenem, meropenem, chloram-
phenicol, clindamycin or macrolides. 
While the invention has been described with a certain 
degree of particularity, it is understood that the invention is 
45 not limited to the embodiment( s) set for herein for purposes of 
exemplification, but is to be limited only by the scope of the 
attached claim or claims, including the full range of equiva-
lency to which each element thereof is entitled. 
The compounds of Formula I or salts, solvates, hydrates or 
prodrugs thereof may be orally administered, for example, 
with an inert diluent or with an assimilable edible carrier, or 
they may be enclosed in hard or soft shell gelatin capsules, or 
they may be compressed into tablets, or they may be incor-
porated directly with the food of the diet. For oral therapeutic 
administration, the compound may be incorporated with 50 
excipient and used in the form of ingestible tablets, buccal 
tablets, troches, capsules, elixirs, suspensions, syrups, 
wafers, and the like. 
Compounds of Formula I or salts, solvates, hydrates or 
prodrugs thereof may also be administered parenterally or 
intraperitoneally. Solutions of the compound can be prepared 
in water suitably mixed with a surfactant such as hydroxypro-
pylcellulose. Dispersions can also be prepared in glycerol, 
liquid polyethylene glycols, DMSO and mixtures thereof 
with or without alcohol, and in oils. Under ordinary condi-
tions of storage and use, these preparations contain a preser-
vative to prevent the growth of microorganisms. A person 




Pharmaceutical compositions suitable for injectable use 65 
include sterile aqueous solutions or dispersion and sterile 
powders for the extemporaneous preparation of sterile inject-
What is claimed is: 
1. A method of treating an anthrax infection in a subject in 
need of such treatment wherein a compound of formula (I) 
(I) 
NH2 0 R3 
N ~ 1:)) )l Q 
H2N N R2 
N~ # 
wherein 
Rl and R2 represent, independently of one another: 
unsubstituted C1 _4 alkoxy or morpholino; and 
US 8,268,825 B2 
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R3 represents: 
C1_6 alkyl or C3 _6 cycloalkyl, which both may be unsub-
stituted or substituted with halogen; 
unsubstituted C2 _6 alkenyl; 
16 
wherein 
Rl and R2 represent, independently of one another: 
unsubstituted Cl-4 alkoxy or morpholino and R3 repre-
sents: 
aryl which may be unsubstituted or substituted with, 5 
C1 _4 alkyl, halogen, C1 _4 alkoxy, or substituted C1 _4 
alkoxy, 
Cl-6 alkyl or C3-6 cycloalkyl, which both may be 
unsubstituted or substituted with halogen, 
unsubstituted C2-6 alkenyl; or 
aryl, which may be unsubstituted or substituted with 
phenyl, Cl-4 alkyl, halogen, or Cl-4 alkoxy. or a pharmaceutically acceptable salt thereof; 
is administered to said subject in a quantity effective to 
inhibit, suppress, or expel an anthrax infection in said 10 
subject. 
7. A method according to claim 6, further comprising 
selecting said compound of formula (I) as a candidate for in 
vivo and/or clinical tests based on the efficacy in inhibiting 
DHFR of Bacillus anthracis in vitro found for said com-
pound. 
2. A method according to claim 1, wherein said compound 
is administered for the treatment of an anthrax infection of the 
respiratory tract. 
3. A method according to claim 1, wherein said compound 
is administered for the treatment of cutaneous anthrax infec-
tions. 
4. A method according to claim 1, wherein said compound 
8. The method of claim 1, wherein said unsubstituted C1 _4 
15 alkoxy is methoxy or ethoxy. 
9. The method of claim 1, wherein said C1_6 alkyl is a 
substituted or unsubstituted C3 _5 alkyl. 
is administered for the treatment of an anthrax infection of the 20 
10. The method of claim 9, wherein said unsubstituted C3 _5 
alkyl is selected from the group consisting of propyl, isopro-
pyl, butyl, isobutyl, and 1-ethylpropyl. 
gastrointestinal tract. 
5. A method according to claim 1 wherein said compound 
of formula (I) exhibits in vitro an IC50 value for human DHFR 
which is at least 70 times, more preferably at least 100 times, 
most preferably at least 250 times as high as that for DHFR of 
Bacillus anthracis. 
6. A method for inhibiting DHFR of Bacillus anthracis in 
vitro, comprising determining the inhibition of DHFR of 
Bacillus anthracis by using, in an assay, a compound of 
Formula (I): 
(I) 
NH2 0 R3 
N ~ 1:)) )lb 
H2N N R2 
N~ # 
RI 
11. The method of claim 9, wherein said substituted C3 _5 
alkyl is substituted propyl. 
12. The method of claim 9, wherein said substituted C3 _5 
alkyl is substituted with halogen. 
25 13. The method of claim 9, wherein said halogen is fluo-
nne. 
14. The method of claim 1, wherein said C3 _6 cycloalkyl is 
a C5 _6 cycloalkyl selected from cyclopentyl and cyclohexyl. 
15. The method of claim 1, wherein said unsubstituted C2 _6 30 alkenyl is a C4 alkenyl. 
35 
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16. The method of claim 1, wherein said aryl is a substi-
tuted or unsubstituted 6-carbon ring aryl. 
17. The method of claim 16, wherein said substituted 6-car-
bon ring aryl is substituted with one or more methyl groups, 
halogen, C1_4 alkoxy , or trifluoromethoxy. 
18. The method of claim 17, wherein said halogen is fluo-
nne. 
19. The method of claim 17, wherein said C1 _4 alkoxy is 
methoxy. 
20. The method of claim 11, wherein said substituted C1 _4 
alkoxy is trifluoromethoxy. 
* * * * * 
